A single gene-editing treatment could someday protect against heart disease, high cholesterol, and other common conditions ...
Specific Biologics, a biotechnology company developing precision gene-editing therapies, has completed an oversubscribed $35 ...
A systematic review of 21 studies finds CRISPR/Cas9 therapies for beta-thalassemia and sickle cell disease achieve high ...
Google DeepMind’s Demis Hassabis and John Jumper won half of the 2024 chemistry Nobel for AlphaFold, which predicts the ...
A new review maps how prime editing, a CRISPR-derived tool capable in principle of correcting 89 percent of human pathogenic ...
Global market projected to expand from USD 8.94 billion in 2025 to USD 10.44 billion in 2026, registering an 18.1% CAGR ...
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...
For years, gene editing in food and agriculture was largely a conversation about what might someday be possible.
We look at some of the key biotech developments, companies, and clinical data to watch at AHA Scientific Sessions 2026.
Scientists can now edit genes in precise locations deep in the brain and body without the use of invasive surgery or implants ...
Hong Kong start-up GenEditBio is testing a one-shot gene-editing therapy for TGFBI-related corneal dystrophies, inherited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results